# Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

> **NCT06484153** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 25 (estimated)

## Conditions studied

- To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
- To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer
- Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** Fruquintinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06484153
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-22
- **Primary completion:** 2026-07-22
- **Final completion:** 2026-12-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06484153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06484153, "Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06484153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*